Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS
May 19, 2022 16:01 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression...
Foghorn Therapeutics Provides First Quarter 2022 Corporate Update
May 09, 2022 07:00 ET
|
Foghorn Therapeutics, Inc.
- Foghorn continues to advance three phase 1 studies through selectively targeting the chromatin regulatory system; both FHD-286 and FHD-609 continue to dose escalate and enroll patients with initial...
Foghorn Therapeutics Presents New Preclinical Data on Novel BRG1/BRM Inhibitor FHD-286 at the 2022 AACR Annual Meeting
April 13, 2022 11:30 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn Therapeutics to Present Preclinical Data For FHD-286 at the 2022 AACR Annual Meeting
April 01, 2022 08:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day
March 11, 2022 16:01 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook
March 10, 2022 07:00 ET
|
Foghorn Therapeutics, Inc.
– Initial clinical data for FHD-286 expected in H1’22 and FHD-609 as early as H1’22 – Advancing broad therapeutic pipeline of oncology programs including protein degraders, enzymatic inhibitors and...
Foghorn Therapeutics to Participate at the Cowen’s 42nd Annual Health Care Conference
February 28, 2022 16:05 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn Therapeutics Announces Chief Scientific Officer Succession
January 10, 2022 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Conference
January 07, 2022 16:05 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform
December 13, 2021 06:00 ET
|
Foghorn Therapeutics, Inc.
- Establishes co-development and co-commercialization agreement on Foghorn’s selective BRM program and an additional undisclosed program - Collaboration includes three additional discovery...